- Home
- ABSI vs SLP Comparison
ABSI vs SLP Comparison
Compare ABSI & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | SLP |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.9M | 320.9M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ABSI | SLP |
|---|---|---|
| Price | $5.11 | $15.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $6.96 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 5.1M | 271.5K |
| Earning Date | 05-07-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.64 | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $4,534,000.00 | ★ $59,577,000.00 |
| Revenue This Year | $215.96 | $3.80 |
| Revenue Next Year | $319.10 | $5.90 |
| P/E Ratio | ★ N/A | $55.54 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $2.24 | $11.09 |
| 52 Week High | $6.72 | $34.01 |
Technical Indicators
Market Signals| Indicator | ABSI | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 58.07 |
| Support Level | $2.51 | $14.10 |
| Resistance Level | $5.23 | $15.59 |
| Average True Range (ATR) | 0.57 | 1.08 |
| MACD | -0.14 | -0.09 |
| Stochastic Oscillator | 28.03 | 49.29 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.